Trial Profile
A Phase 1, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cevidoplenib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Oscotec
- 06 Oct 2017 Status changed from recruiting to completed.
- 06 Apr 2016 New trial record